[{"id":"6e960e10-a292-4eb9-ac61-0062dbf094ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT05975073","created_at":"2023-08-03T15:09:55.318Z","updated_at":"2024-07-02T16:34:37.673Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors","source_id_and_acronym":"NCT05975073","lead_sponsor":"Amgen","biomarkers":" MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDE397 • AMG 193"],"overall_status":"Recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 07/27/2023","start_date":" 07/27/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 12/03/2026","study_completion_date":" 12/03/2026","last_update_posted":"2024-06-06"},{"id":"92c00917-1e46-4b94-b994-56d21f87434a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04794699","created_at":"2021-03-12T16:52:33.483Z","updated_at":"2024-07-02T16:35:05.377Z","phase":"Phase 1","brief_title":"Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion","source_id_and_acronym":"NCT04794699","lead_sponsor":"IDEAYA Biosciences","biomarkers":" MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • docetaxel • albumin-bound paclitaxel • pemetrexed • Trodelvy (sacituzumab govitecan-hziy) • IDE397"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 04/14/2021","start_date":" 04/14/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 03/30/2027","study_completion_date":" 03/30/2027","last_update_posted":"2024-05-07"}]